Strategies to examine new compounds for intraperitoneal use in ovarian cancer

International Journal of Gynecological Cancer

Volumn 18, Issue SUPPL. 1, 2008, Pages 33-35

  Markman, M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Cisplatin; Intraperitoneal chemotherapy; Ovarian cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; MITOXANTRONE; PACLITAXEL; PLATINUM DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; HUMAN; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZATION;

ANTINEOPLASTIC AGENTS; DRUG EVALUATION; FEMALE; HUMANS; INFUSIONS, PARENTERAL; OVARIAN NEOPLASMS;

EID: 40749162812     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01102.x     Document Type: Article

References (18)

1. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996 335 : 1950 5.
2. Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001 19 : 1001 7.
3. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006 354 : 34 43.
4. Elit L, Oliver TK, Covens A et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 2007 109 : 692 702.
5. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978 62 : 1 9.
6. Ozols RF, Young RC, Speyer JL et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 1982 42 : 4265 9.
7. Litterst CL, Collins JM, Lowe MC et al. Local and systemic toxicity resulting from large-volume ip administration of doxorubicin in the rat. Cancer Treat Rep 1982 66 : 157 61.
8. Roboz J, Jacobs AJ, Holland JF et al. Intraperitoneal infusion of doxorubicin in the treatment of gynecologic carcinomas. Med Pediatr Oncol 1981 9 : 245 50.
9. Demicheli R, Bonciarelli G, Jirillo A et al. Pharmacologic data and technical feasibility of intraperitoneal doxorubicin administration. Tumori 1985 71 : 63 8.
10. Markman M, Howell SB, Lucas WE et al. Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. J Clin Oncol 1984 2 : 1321 6.
11. Alberts DS, Young L, Mason N, Salmon SE. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 1985 12 : 38 42.
12. Alberts DS, Surwit EA, Peng YM et al. Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. Cancer Res 1988 48 : 5874 7.
13. Markman M, George M, Hakes T et al. Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. J Clin Oncol 1990 8 : 146 50.
14. Andrews PA, Velury S, Mann SC, Howell SB. cis- Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 1988 48 : 68 73.
15. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2003 4 : 277 83.
16. Markman M. Intraperitoneal drug delivery of antineoplastics. Drugs 2001 61 : 1057 65.
17. Francis P, Rowinsky E, Schneider J et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 1995 13 : 2961 7.
18. Markman M, Brady MF, Spirtos NM et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998 16 : 2620 4.